Literature DB >> 34561849

Serial changes in cardiac sympathetic nervous function after transcatheter aortic valve replacement: A prospective observational study using 123I-meta-iodobenzylguanidine imaging.

Yoshito Kadoya1, Kan Zen2, Nagara Tamaki3, Shunsuke Nakamura1, Tomotaka Fujimoto1, Masaki Yashige1, Kazuaki Takamatsu1, Nobuyasu Ito1, Michiyo Yamano1, Tetsuhiro Yamano1, Takeshi Nakamura1, Hidetake Kawajiri4, Satoshi Numata4, Hitoshi Yaku4, Satoaki Matoba1.   

Abstract

BACKGROUND: Transcatheter aortic valve replacement (TAVR) can rapidly improve cardiac sympathetic nervous function (CSNF) within 2 weeks in patients with aortic stenosis (AS). However, whether such short-term improvements will be sustained thereafter remains unclear.
METHODS: Patients with severe AS who underwent TAVR between October 2017 and June 2019 were enrolled in this single-center, prospective, observational study. 123I-meta-iodobenzylguanidine imaging was performed at baseline, within 2 weeks after TAVR, and at 6 to 12 months post-TAVR to evaluate the heart-mediastinum ratio (H/M) and washout rate.
RESULTS: Of 183 consecutive patients, 75 (19 men; median age: 86 years) were evaluated. The late H/M significantly improved within 2 weeks after TAVR (P = .041) and further improved over 6 to 12 months after TAVR (P = .041). Multivariate analysis revealed that the baseline mean aortic valve pressure gradient (mPG) was an independent predictor of mid-term improvement in the late H/M (> 0.1) (P = .037). Patients with a high baseline mPG (≥ 58 mmHg) exhibited a significantly greater increase in the late H/M than those with a low baseline mPG (< 42 mmHg) (0.24 vs 0.01; P = .029).
CONCLUSION: CSNF demonstrated sustained improvement from within 2 weeks after TAVR until 6 to 12 months later. Such improvement was related to baseline hemodynamic AS severity.
© 2021. American Society of Nuclear Cardiology.

Entities:  

Keywords:  123I-meta-iodobenzylguanidine imaging; aortic stenosis; cardiac sympathetic nervous function; transcatheter aortic valve replacement

Mesh:

Substances:

Year:  2021        PMID: 34561849     DOI: 10.1007/s12350-021-02799-0

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  20 in total

1.  ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure.

Authors:  Y Takeishi; H Atsumi; S Fujiwara; K Takahashi; H Tomoike
Journal:  J Nucl Med       Date:  1997-07       Impact factor: 10.057

Review 2.  Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Authors:  Arnold F Jacobson; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

Review 3.  Aortic-valve stenosis--from patients at risk to severe valve obstruction.

Authors:  Catherine M Otto; Bernard Prendergast
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

4.  Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging.

Authors:  Koichi Okuda; Kenichi Nakajima; Tetsuo Hosoya; Takehiro Ishikawa; Takahiro Konishi; Kosuke Matsubara; Shinro Matsuo; Seigo Kinuya
Journal:  J Nucl Cardiol       Date:  2010-11-23       Impact factor: 5.952

5.  Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure.

Authors:  Alain Cohen-Solal; François Rouzet; Alain Berdeaux; Dominique Le Guludec; Eric Abergel; André Syrota; Pascal Merlet
Journal:  J Nucl Med       Date:  2005-11       Impact factor: 10.057

6.  Early effects of transcatheter aortic valve replacement on cardiac sympathetic nervous function assessed by 123I-metaiodobenzylguanidine scintigraphy in patients with severe aortic valve stenosis.

Authors:  Yoshito Kadoya; Kan Zen; Nagara Tamaki; Nobuyasu Ito; Kensuke Kuwabara; Michiyo Yamano; Tetsuhiro Yamano; Takeshi Nakamura; Shigenori Matsushima; Katsuhiko Oka; Satoshi Numata; Hitoshi Yaku; Satoaki Matoba
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-09       Impact factor: 9.236

7.  A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure.

Authors:  Tomoaki Nakata; Kenichi Nakajima; Shohei Yamashina; Takahisa Yamada; Mitsuru Momose; Shu Kasama; Toshiki Matsui; Shinro Matsuo; Mark I Travin; Arnold F Jacobson
Journal:  JACC Cardiovasc Imaging       Date:  2013-07

8.  Transcatheter Aortic Valve Implantation Improves Cardiac Sympathetic Nerve Activity on 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Severe Aortic Valve Stenosis.

Authors:  Mitsuo Sobajima; Hiroshi Ueno; Hiroshi Onoda; Hiroyuki Kuwahara; Shuhei Tanaka; Ryuichi Ushijima; Nobuyuki Fukuda; Shigeki Yokoyama; Saori Nagura; Toshio Doi; Akio Yamashita; Kazuaki Fukahara; Hisakatsu Ito; Koichiro Kinugawa
Journal:  Circ J       Date:  2017-09-29       Impact factor: 2.993

Review 9.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Catherine M Otto; Rick A Nishimura; Robert O Bonow; Blase A Carabello; John P Erwin; Federico Gentile; Hani Jneid; Eric V Krieger; Michael Mack; Christopher McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson; Christopher Toly
Journal:  Circulation       Date:  2020-12-17       Impact factor: 29.690

10.  Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure.

Authors:  Caroline E Veltman; Mark J Boogers; Joris E Meinardi; Imad Al Younis; Petra Dibbets-Schneider; Ernst E Van der Wall; Jeroen J Bax; Arthur J H A Scholte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.